110 related articles for article (PubMed ID: 1877392)
1. Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate.
Esswein A; Hänseler E; Montejano Y; Vitols KS; Huennekens FM
Adv Enzyme Regul; 1991; 31():3-12. PubMed ID: 1877392
[TBL] [Abstract][Full Text] [Related]
2. Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.
Haenseler E; Esswein A; Vitols KS; Montejano Y; Mueller BM; Reisfeld RA; Huennekens FM
Biochemistry; 1992 Jan; 31(3):891-7. PubMed ID: 1731945
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.
Vitols KS; Haag-Zeino B; Baer T; Montejano YD; Huennekens FM
Cancer Res; 1995 Feb; 55(3):478-81. PubMed ID: 7834611
[TBL] [Abstract][Full Text] [Related]
4. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
5. Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates.
Huennekens FM
Adv Enzyme Regul; 1997; 37():77-92. PubMed ID: 9381987
[TBL] [Abstract][Full Text] [Related]
6. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
[TBL] [Abstract][Full Text] [Related]
7. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
8. Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.
Perron MJ; Page M
Br J Cancer; 1996 Feb; 73(3):281-7. PubMed ID: 8562331
[TBL] [Abstract][Full Text] [Related]
9. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs.
Hamstra DA; Pagé M; Maybaum J; Rehemtulla A
Cancer Res; 2000 Feb; 60(3):657-65. PubMed ID: 10676650
[TBL] [Abstract][Full Text] [Related]
10. An antimelanoma-barley ribosome inactivating protein conjugate is cytotoxic to melanoma cells in vitro.
Ovadia M; Hager CC; Oeltmann TN
Anticancer Res; 1990; 10(3):671-5. PubMed ID: 2369082
[TBL] [Abstract][Full Text] [Related]
11. Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer.
Umemoto N; Kato Y; Endo N; Takeda Y; Hara T
Int J Cancer; 1989 Apr; 43(4):677-84. PubMed ID: 2784785
[TBL] [Abstract][Full Text] [Related]
12. Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides.
Kuefner U; Lohrmann U; Montejano YD; Vitols KS; Huennekens FM
Biochemistry; 1989 Mar; 28(5):2288-97. PubMed ID: 2719954
[TBL] [Abstract][Full Text] [Related]
13. Monensin is obligatory for the cytotoxic action of a disulfide linked methotrexate-anti-transferrin receptor conjugate.
Raso V; Fehrmann C; Solan VC; Rosowsky A
Biochem Biophys Res Commun; 1988 Jan; 150(1):104-10. PubMed ID: 3276306
[TBL] [Abstract][Full Text] [Related]
14. Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates.
Endo N; Takeda Y; Umemoto N; Kishida K; Watanabe K; Saito M; Kato Y; Hara T
Cancer Res; 1988 Jun; 48(12):3330-5. PubMed ID: 3259466
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody.
Umemoto N; Kato Y; Hara T
Cancer Immunol Immunother; 1989; 28(1):9-16. PubMed ID: 2783302
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and selectivity of monoclonal-antibody-targeted drugs and free methotrexate in fluorescence-labelled mixed tumour-cell monolayer cultures and multicellular spheroids.
Embleton MJ; Charleston A; Affleck K
Int J Cancer; 1991 Oct; 49(4):566-72. PubMed ID: 1917158
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities.
Kralovec J; Spencer G; Blair AH; Mammen M; Singh M; Ghose T
J Med Chem; 1989 Nov; 32(11):2426-31. PubMed ID: 2810330
[TBL] [Abstract][Full Text] [Related]
19. Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2.
Laethem RM; Blumenkopf TA; Cory M; Elwell L; Moxham CP; Ray PH; Walton LM; Smith GK
Arch Biochem Biophys; 1996 Aug; 332(1):8-18. PubMed ID: 8806703
[TBL] [Abstract][Full Text] [Related]
20. Occurrence and significance of diastereomers of methotrexate alpha-peptides.
Kuefner U; Esswein A; Lohrmann U; Montejano Y; Vitols KS; Huennekens FM
Biochemistry; 1990 Nov; 29(46):10540-5. PubMed ID: 2271663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
